On May 18, 2017 Novartis reported it will present data from across its oncology portfolio at the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), being held June 2-6 in Chicago; the 14th International Conference on Malignant Lymphoma (ICML), being held June 14-17 in Lugano, Switzerland; and the 22nd Annual Congress of the European Hematology Association (EHA) (Free EHA Whitepaper), being held June 22-25 in Madrid (Press release, Novartis, MAY 18, 2017, View Source [SID1234519243]). With more than 75 abstracts accepted, data will highlight research across 34 compounds in key disease areas, including breast and lung cancers, melanoma, leukemia and other blood disorders, and myeloproliferative neoplasms (MPNs). Schedule your 30 min Free 1stOncology Demo! "Our presence at key medical congresses this year is marked by our innovation in targeted therapies and immuno-oncology in difficult to treat cancers," said Bruno Strigini, CEO, Novartis Oncology. "We are particularly excited to show the first data from the JULIET trial, which evaluates the use of CTL019 in relapsed/refractory diffuse large B-cell lymphoma. These results, along with the data that led to our filing for CTL019 in relapsed/refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia, demonstrate our commitment to research in this area."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Novartis data at the 2017 ASCO (Free ASCO Whitepaper) Annual Meeting will highlight the following:
Update on outcomes with Kisqali* (ribociclib) in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer:
Updated Results from MONALEESA-2, a Phase 3 Trial of First-Line Ribociclib + Letrozole in Hormone Receptor-Positive (HR+), HER2-Negative (HER2-), Advanced Breast Cancer (ABC) [Abstract #1038; Sunday, June 4, 8:00 AM CDT]
Health-Related Quality of Life (HRQoL) of Postmenopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) Treated with Ribociclib + Letrozole: Results from MONALEESA-2 [Abstract #1020; Sunday, June 4, 8:00 AM CDT]
Data showing patient-reported quality of life outcomes for CTL019** (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed/refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL):
Patient-Reported Quality of Life (QOL) Following CTL019 in Pediatric and Young Adult Patients (pts) with Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) [Abstract #10523; Sunday, June 4, 8:00 AM CDT]
New data evaluating long-term outcomes with Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy in patients with BRAF V600-mutated unresectable or metastatic melanoma as well as data from patients with other tumor types:
Five-Year Overall Survival (OS) Update from a Phase II, Open-Label Trial of Dabrafenib (D) and Trametinib (T) in Patients (pts) with BRAF V600-Mutant Unresectable or Metastatic Melanoma (MM) [Abstract #9505; Sunday, June 4, 9:24 AM CDT]
COMBI-MB: A Phase II Study of Combination Dabrafenib (D) and Trametinib (T) in Patients with BRAF V600-Mutant (mut) Melanoma Brain Metastases (MBM) [Abstract #9506; Sunday, June 4, 10:00 AM CDT]
Updated Survival of Patients (pts) with Previously Treated BRAF V600E-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) who Received Dabrafenib (D) or D + Trametinib (T) in the Phase II BRF113928 Study [Abstract #9075; Saturday, June 3, 8:00 AM CDT]
Efficacy of Dabrafenib (D) and Trametinib (T) in Patients (pts) with BRAF V600E-Mutated Anaplastic Thyroid Cancer (ATC) [Abstract #6023; Monday, June 5, 1:15 PM CDT]
New data on Zykadia (ceritinib) as well as the investigational compound EGF816 which highlight continued investigations in the treatment of mutation-driven lung cancer:
Ceritinib Plus Nivolumab (NIVO) in Patients (pts) with Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) [Abstract #2502; Saturday, June 3, 1:39 PM CDT]
Genomic Profiling of Resistant Tumor Samples Following Progression on EGF816, a Third Generation, Mutant-Selective EGFR Tyrosine Kinase Inhibitor (TKI), in Advanced Non-Small Cell Lung Cancer (NSCLC) [Abstract #11506; Sunday, June 4, 9:48 AM CDT]
Adjuvant treatment of renal cell carcinoma (RCC) and safety and efficacy of combination therapy in treatment of advanced RCC:
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Locally Advanced Renal Cell Carcinoma (RCC) (PROTECT) [Abstract #4507; Monday, June 5, 10:12 AM CDT]
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib (PAZ) and Pembrolizumab (PEM) in Patients (pts) with Advanced Renal Cell Carcinoma (aRCC) [Abstract #4506; Monday, June 5, 9:36 AM CDT]
Additional data presented at ASCO (Free ASCO Whitepaper) include:
Phase III Study of Lapatinib (L) Plus Trastuzumab (T) and Aromatase Inhibitor (AI) vs T+AI vs L+AI in Postmenopausal Women (PMW) with HER2+, HR+ Metastatic Breast Cancer (MBC): ALTERNATIVE [Abstract #1004; Saturday, June 3, 2:27 PM CDT]
Everolimus (EVE) Plus Endocrine Therapy in Patients with Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (BC): First and Second-Line Data from the BOLERO-4 Study [Abstract #1010; Sunday, June 4, 8:00 AM CDT]
Cognitive Technology Addressing Optimal Cancer Clinical Trial Matching and Protocol Feasibility in a Community Cancer Practice [Abstract #6501; Monday, June 5, 8:12 AM CDT]
Sandoz, a Novartis division, the pioneer and global leader in biosimilars, will present data for Zarxio, the company’s filgrastim biosimilar:
Safety and Efficacy of Alternating Treatment with EP2006, a Filgrastim Biosimilar, and Reference Filgrastim for the Prevention of Severe Neutropenia, in Patients with Breast Cancer Receiving Myelosuppressive Chemotherapy [Abstract #10116; Saturday, June 3, 1:15 PM CDT]
Novartis data at the 14th Meeting of ICML will highlight data from the multi-center Phase II JULIET study evaluating the efficacy and safety of CTL019 in adult patients with r/r diffuse large B-cell lymphoma (DLBCL):
Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 in Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) – An Interim Analysis [Abstract #007; Wednesday, June 14, 3:40 PM CEST]
Novartis data at the 2017 EHA (Free EHA Whitepaper) Annual Congress will highlight the following:
Data evaluating CTL019** outcomes in r/r pediatric and young adult patients with B-ALL:
Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis [Abstract #S476; Saturday, June 24, 4:00 PM CEST]
Analysis of Safety Data from 2 Multicenter Trials of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) [Abstract #P517; Saturday, June 24, 5:30 PM CEST]
CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) [Abstract #S477; Saturday, June 24, 4:15 PM CEST]
New analyses of ENESTfreedom and ENESTop evaluating Treatment-free Remission (TFR) at 96-week follow-up in patients meeting rigorous criteria for treatment discontinuation:
Durable Treatment-free Remission (TFR) After Stopping Second-line Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTop 96-Wk Update [Abstract #P257; Friday, June 23, 5:15 PM CEST]
Durable Treatment-free Remission (TFR) Following Frontline Nilotinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom 96-Wk Update [Abstract #P601; Saturday, June 24, 5:30 PM CEST]
Pooled survival analysis of two clinical trials evaluating Rydapt (midostaurin) in adult patients with advanced systemic mastocytosis:
Pooled Survival Analysis of Midostaurin Clinical Study Data (D2201 + A2213) in Patients with Advanced Systemic Mastocytosis (ADVSM) Compared with Historical Controls [Abstract #S788; Sunday, June 25, 9:00 AM CEST]
New data in myeloproliferative neoplasms, including a long-term analysis evaluating Jakavi (ruxolitinib)*** in patients with inadequately controlled polycythemia vera in a less advanced phase of the disease:
Ruxolitinib For The Treatment Of Inadequately Controlled Polycythemia Vera Without Splenomegaly: 80-Week Follow-Up From The RESPONSE-2 Trial [Abstract #S784; Sunday, June 25, 8:00 AM CEST]
Comparing The Safety And Efficacy Of Ruxolitinib (Rux) In Patients (Pts) With DIPSS Low/Intermediate-1-, Intermediate-2-, And High-Risk Myelofibrosis (MF) In JUMP, A Phase 3b, Expanded-Access Study [Abstract #E1333; Friday, June 23, 9:30 AM CEST]
Treatment and Management Of Patients With MPNs – Findings From the International MPN LANDMARK Survey [Abstract #P706; Saturday, June 24, 5:30 PM CEST]
Perception Of Symptom Burden and Treatment Goals Between Physicians and Patients With MPNs: An Analysis From the International MPN LANDMARK Survey [Abstract #E1320; Friday, June 23, 9:30 AM CEST]
Additional data presented at EHA (Free EHA Whitepaper) include:
Mediation by Patient-Reported Outcomes on the Association Between Film-Coated versus Dispersible Formulations of Deferasirox and Serum Ferritin Reduction: A Post-Hoc Analysis of the ECLIPSE Trial [Abstract #P286; Friday, June 23, 5:15 PM CEST]
Crizanlizumab, a P-selectin Inhibitor, Increases the Likelihood of Not Experiencing a Sickle Cell-Related Pain Crisis While on Treatment: Results from the Phase II SUSTAIN Study [Abstract #S454; Saturday, June 24, 12:15 PM CEST]
Throughout the 2017 ASCO (Free ASCO Whitepaper) Annual Meeting, ICML meeting and EHA (Free EHA Whitepaper) Annual Meeting, Novartis Oncology will host dedicated content on the Novartis Oncology website (View Source) that will feature unique insights and perspectives on emerging areas of cancer care and research.
Product Information
Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.
For full prescribing information, including approved indications and important safety information about marketed products, please visit
View Source
EGF816, CTL019 and crizanlizumab (SEG101, formerly SelG1) are investigational compounds. Efficacy and safety have not been established. There is no guarantee these compounds will become commercially available.